US-based life sciences investment firm Foresite Capital has closed a $668m fund that included several unnamed university endowments among the limited partners.

The investors in Fund IV also included pension funds, insurance providers and foundations, though none of them have been identified. Foresite noted that the limited partners are a mix of new and existing backers.

Foresite Capital, founded in 2011, now has $2bn of assets under management. The firm focuses on private and public healthcare companies, targeting areas such as therapeutics, discovery and data science and clinical care.

The firm has been increasingly interested in data science and machine learning, recently hiring additional staff to drive its portfolio in that area.

Jim Tananbaum, chief executive and founder of Foresite, said: “At Foresite Capital we have brought together a unique value proposition for our portfolio companies. We not only provide capital from seed to public stage, but also a multidisciplinary team of scientists, clinicians, analysts and engineers who collaborate to seek the best data-driven decisions.

“The ability to ingest and derive meaning from massive amounts of complex information is a critical success factor in healthcare investing. We are pleased by the confidence and enthusiasm our Fund IV investors have demonstrated in the Foresite Capital team, as well as the progress made by our rapidly developing portfolio.”